The DOI matches its Crossref record.
CHOLINERGIC APPROACHES TO THE TREATMENT OF ALZHEIMER'S DISEASE
Abstract
Aizheimer's disease (AD) is a major mental health problem involving abnormalities of several neurotransmitter systems in the brain. The most consistent and pervasive abnormality involves the cholmergic system, and correlates with severity of illness in AD. Pharmacological enhancement of cholinergic activity includes presynaptic agents which increase acetylcholine (ACh) synthesis and release; synaptic agents which increase ACh by limiting its breakdown; and postsynaptic agents which directly stimulate ACh receptors. Valid trials of cholinergic agents in AD require a specialized study design in which individualized optimal drug doses are tested in a large population of stringently diagnosed AD patients. Testing devices must be suitable for each patient's capabilities, and should measure alterations of function in several areas. Clinical trials with choline and lecithin, ACh precursors, have not shown cognitive improvements in AD patients. Combination of precursors with agents that enhance the firing rate of presynaptic neurons, such as piracetam, may have some beneficial effect in a subgroup of AD patients with remaining functionally intact cholinergic neurons. Red cell-plasma choline ratio appears to be higher in treatment responders. Presynaptic approaches have the advantage of mimicking the phasic action of cholinergic cells, but require the presence of functionally intact cholinergic neurons. Physostigmine, an acetycholinesterase (AChE) inhibitor, augments available synaptic ACh. Studies with intravenous physostigmine show significant but moderate transient improvement in memory test, but applicability is limited by short half-life. Oral, like intravenous, physostigmine has a narrow therapeutic window, necessitating the use of a dose-finding phase in study design. Oral physostigmine has yielded modest improvements in specific cognitive areas and overall functioning in a majority of AD patients. Biochemical measures of central cholinergic activity such as plasma cortisol and cerebrospinal fluid AChE activity have been correlated with symptom improvement, and may identify likely responders. Cholinergic agonists such as Rs 86, erecoline and oxotremorine have been used in preliminary trials with AD patients, yielding modest results with significant side effects. Future directions include the development of more specific, long-acting cholinergic agents with fewer side effects; differentiating M-1 and M-2 receptor sites; delineation of parameters that can predict response, and possibly the use of combined neurotransmitter enhancement treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cholinergic function and intellectual decline in Alzheimer's disease
Collerton, D. (1986) · Neuroscience · doi:10.1016/0306-4522(86)90002-3 · Cited by 601
Heinrich, M., & Lee Teoh, H. (2004) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.02.012 · Cited by 584
Sugimoto, H., Iimura, Y., Yamanishi, Y., & Yamatsu, K. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00024a009 · Cited by 341
Belanoff, J. K., Gross, K., Yager, A., & Schatzberg, A. F. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00018-8 · Cited by 310
Modelling dementia: Effects of scopolamine on memory and attention
Broks, P., Preston, G. C., Traub, M., Poppleton, P., Ward, C., & Stahl, S. M. (1988) · Neuropsychologia · doi:10.1016/0028-3932(88)90004-8 · Cited by 220
Metadata
- Authors
- Hollander, E., Mohs, R. C., & Davis, K. L.
- Venue
- British Medical Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 1986
- Volume
- 42
- Issue
- 1
- Pages
- 97-100
- ISSN
- 0007-1420 (ISSN-L)
- 1471-8391
- OpenAlex
- W2344563485
- Cited by
- 158
- References
- 0
- FWCI
- 15.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CHOLINERGIC APPROACHES TO THE TREATMENT OF ALZHEIMER'S DISEASE. https://app.cochat.ai/papers/10.1093/oxfordjournals.bmb.a072106
- The paper
- Hollander, E., Mohs, R. C., & Davis, K. L. (1986). CHOLINERGIC APPROACHES TO THE TREATMENT OF ALZHEIMER'S DISEASE. British Medical Bulletin. https://doi.org/10.1093/oxfordjournals.bmb.a072106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.